(3S)-3-氨基-5-甲基-己酸叔丁酯 | 166023-30-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (3S)-3-氨基-5-甲基-己酸叔丁酯
• 中文别名: 叔丁基(3S)-3-氨基-5-甲基己酸酯；(3S)-3-氨基-5-甲基己酸叔丁酯
• 英文名称: 1,1-dimethylethyl (3S)-3-amino-5-methylhexanoate
• 英文别名: (S)-tert-butyl 3-amino-5-methylhexanoate；tert-butyl (S)-3-amino-5-methylhexanoate；H-D-β-HoLeu-O^tBu；L-β-HoLeu-O-t-Bu；tert-butyl (3S)-3-amino-5-methylhexanoate
• CAS: 166023-30-9
• 化学式: C₁₁H₂₃NO₂
• 分子量: 201.309
• InChiKey: WBOPVTYXLFEVGP-VIFPVBQESA-N

物化性质

• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

SDS

Name:	tert-Butyl (3S)-3-Amino-5-Methylhexanoate 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	166023-30-9

Section 1 - Chemical Product MSDS Name:tert-Butyl (3S)-3-Amino-5-Methylhexanoate 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
166023-30-9	tert-Butyl (3S)-3-Amino-5-Methylhexano	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 166023-30-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H23NO2
Molecular Weight: 201.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 166023-30-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl (3S)-3-Amino-5-Methylhexanoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 166023-30-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 166023-30-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 166023-30-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3S)-3-氨基-5-甲基-己酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以92%的产率得到L-β-高亮氨酸
  参考文献：
  名称：

  平行合成手性β-氨基酸

  摘要：

  使用高手性锂N-苄基-N-（α-甲基苄基）酰胺的共轭加成，完成了对映体纯度高的30个β-氨基酸阵列的平行不对称合成。该协议的实验简单性和高度实用性通过高15种α，β-不饱和酯的高效平行转化为相应β-氨基酸的对映体系列以高总收率和选择性进行了证明，且每个步骤的纯化步骤最少反应方案。

  DOI：

  10.1016/j.tetasy.2007.06.008
• 作为产物：
  描述：

  2-甲基-2-丙基(2E)-5-甲基-2-己烯酸酯 在 palladium dihydroxide 正丁基锂 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 为溶剂， -78.0~20.0 ℃ 、101.33 kPa 条件下， 反应 27.5h， 生成 (3S)-3-氨基-5-甲基-己酸叔丁酯
  参考文献：
  名称：

  平行合成手性β-氨基酸

  摘要：

  使用高手性锂N-苄基-N-（α-甲基苄基）酰胺的共轭加成，完成了对映体纯度高的30个β-氨基酸阵列的平行不对称合成。该协议的实验简单性和高度实用性通过高15种α，β-不饱和酯的高效平行转化为相应β-氨基酸的对映体系列以高总收率和选择性进行了证明，且每个步骤的纯化步骤最少反应方案。

  DOI：

  10.1016/j.tetasy.2007.06.008

文献信息

• Discovery of a novel small molecule agonist scaffold for the APJ receptor
  作者：Sanju Narayanan、Rangan Maitra、Jeffery R. Deschamps、Katherine Bortoff、James B. Thomas、Yanyan Zhang、Keith Warner、Vineetha Vasukuttan、Ann Decker、Scott P. Runyon

  DOI：10.1016/j.bmc.2016.06.018

  日期：2016.8

  coupled apelin receptor (APJ, AGTRL-1, APLNR). The APJ receptor is an attractive therapeutic target because of its involvement in cardiovascular diseases and potentially other disorders including liver fibrosis, obesity, diabetes, and neuroprotection. To date, pharmacological characterization of the APJ receptor has been limited due to the lack of small molecule functional agonists or antagonists.

  Apelinergic系统包括一系列内源性肽apelin，ELABELA / TODDLER及其7跨膜G蛋白偶联apelin受体（APJ，AGTRL-1，APNLR）。APJ受体是一种有吸引力的治疗靶标，因为它参与了心血管疾病和潜在的其他疾病，包括肝纤维化，肥胖，糖尿病和神经保护。迄今为止，由于缺乏小分子功能性激动剂或拮抗剂，APJ受体的药理学表征受到限制。通过重点筛选，我们确定了一种药物样小分子激动剂，其功能EC 50值为21.5±5μM，结合亲和力（K i）为5.2± 0.5μM，命中1。初步的结构活性研究提供了化合物具有效力增强27倍的22和第一亚微摩尔全激动剂，EC 50值为800±0.1 nM，K i为1.3±0.3μM。初步的SAR，合成方法和体外药理学表征表明，该支架将成为进一步改善APJ效能和选择性的有利起点。 下载：下载全图
• Tantalum-Catalyzed Amidation of Amino Acid Homologues
  作者：Wataru Muramatsu、Hisashi Yamamoto

  DOI：10.1021/jacs.9b08415

  日期：2019.12.4

  tantalum-catalyzed solvent-free approach for the construction of amide bonds with 1-(trimethylsilyl)imidazole is developed, and the mild reaction conditions are applicable to a wide variety of electrophilic amino acid homologs. This approach delivers a new class of peptides in high yields without any epimerization.

  开发了一种钽催化的无溶剂方法，用于与 1-（三甲基甲硅烷基）咪唑构建酰胺键，并且反应条件温和，适用于多种亲电氨基酸同系物。这种方法以高产率提供了一类新的肽，而没有任何差向异构化。
• Peptide Bond Formation of Amino Acids by Transient Masking with Silylating Reagents
  作者：Wataru Muramatsu、Hisashi Yamamoto

  DOI：10.1021/jacs.1c02600

  日期：2021.5.12

  A one-pot peptide bond-forming reaction has been developed using unprotected amino acids and peptides. Two different silylating reagents, HSi[OCH(CF3)2]3 and MTBSTFA, are instrumental for the successful implementation of this approach, being used for the activation and transient masking of unprotected amino acids and peptides at C-termini and N-termini, respectively. Furthermore, CsF and imidazole

  使用未受保护的氨基酸和肽开发了一种一锅式肽键形成反应。两种不同的甲硅烷基化试剂 HSi[OCH(CF 3 ) 2 ] 3和 MTBSTFA 有助于成功实施该方法，用于激活和瞬时掩蔽C端和N端未受保护的氨基酸和肽， 分别。此外，CsF 和咪唑用作催化剂，活化 HSi[OCH(CF 3 ) 2 ] 3并且还加速化学选择性硅烷化。这种方法是通用的，因为它可以容忍带有一系列官能团的侧链，同时提供高达 99% 以上的相应肽收率，而无需任何外消旋或聚合。
• [EN] APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APELINE (APJ) ET LEURS UTILISATIONS
  申请人：RES TRIANGLE INST

  公开号：WO2015188073A1

  公开（公告）日：2015-12-10

  This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

  这项披露涉及到apelin受体（APJ）的激动剂以及这些激动剂的用途。
• APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF
  申请人：RUNYON Scott P.

  公开号：US20160207889A1

  公开（公告）日：2016-07-21

  This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

  本披露涉及到apelin受体（APJ）激动剂及其使用。